Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease
If approved, Forxiga has the potential to change the treatment paradigm for millions of people in the EU suffering from chronic kidney diseaseAstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the DAPA-CKD Phase III trial that showed Forxiga, on top of standard-of-care treatment with an angiotensin-converting